Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome) Treatments
Find Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome) Treatments
Brand Name
Mepsevii
Generic Name
Vestronidase
View Brand Information FDA approval date: November 15, 2017
Classification: Lysosomal beta Glucuronidase
Form: Injection
What is Mepsevii (Vestronidase)?
MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII . Limitations of Use The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined. MEPSEVII is a recombinant human lysosomal beta glucuronidase indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII . Limitations of Use The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
Summary: The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.